Clinical trial NCT00094536: Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Official title: A Study to Evaluate the Effectiveness of Extended Treatment Regimens With the Her Option® Cryoablation Therapy System for Treatment of Menorrhagia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Menorrhagia
Keywords: Menorrhagia
Excessive Uterine Bleeding
Cryoablation
Menstrual disorder
Endometrial ablation
Abnormal uterine bleeding
Dysfunctional uterine bleeding
Lead sponsor: CooperSurgical Inc.
Sponsor class: INDUSTRY
First posted: 2004-10-21
Enrollment: 82
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The Her Option® Cryoablation Therapy System is a closed-loop cryosurgical device that is used to ablate the endometrial lining in pre-menopausal women with menorrhagia (excessive menstrual bleeding) due to benign causes. This is a non-incisional procedure, which can be performed in a physicians office with minimal sedation.

Initial FDA clinical studies were conducted with a two-freeze treatment pattern consisting of a 4 minute freeze with the Cryoprobe positioned in one cornu followed by a second freeze of 6 minutes with the Cryoprobe repositioned in the contralateral cornu.

Since completion of the early studies, many physicians have experimented with varying freeze patterns using longer freeze durations and/or additional freezes at the fundus and the lower uterine segment. The results, as reported in the literature, indicate that these extended freeze patterns produce significantly better results than the original regimen.

Detailed description: American Medical Systems, Inc. (AMS) hypothesized that the original treatment pattern used to support a previous FDA approval for the Her Option® Cryoablation Therapy System for Treatment of abnormal uterine bleeding was not optimal and that extended freeze regimens will result in improved outcomes for patients.

Eligibility criteria: Inclusion Criteria:

* Pre-menopausal adult women 30 years of age or older who have completed childbearing
* Heavy or prolonged menstrual bleeding
* Willing and able to complete all follow-up exams as required by protocol

Exclusion Criteria:

* Known or suspected endometrial cancer or pre-malignant change of the endometrium
* Untreated cervical dysplasia
* Hereditary malformations of the uterine cavity that would prevent insertion and/or placement of the cryoprobe
* Uterine myomas \> or = to 3 cm in diameter
* Past history of invasive treatment for abnormal uterine bleeding or uterine myomas
* History of classical (not low transverse incision) cesarean section
* Active genital or urinary tract infection or acute pelvic inflammatory disease (PID)
* Intrauterine device (IUD) in place
* Other medical conditions could be exclusionary upon evaluation for study treatment

Primary outcomes:
measure: Success (Reduction in Menstruation to Normal Levels)
timeFrame: 1 Year
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Kelly Roy, M.D., P.C.
state: Arizona
city: Wellington
country: United States
facility: Institute for Women's Health & Body
state: Florida
city: Burlington
country: United States
facility: Lahey Clinic
state: Massachusetts
city: Saginaw
country: United States
facility: Valley OB/GYN
state: Michigan
city: Charlotte
country: United States
facility: Center for Endometrial Ablation
state: North Carolina
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Camp Hill
country: United States
facility: Jose Manjon, M.D. (Private practice)
state: Pennsylvania
Study officials:
References: